Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud's phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036488 | PMC |
| http://dx.doi.org/10.1177/2042098620905976 | DOI Listing |
Publication Analysis
Top Keywords
raynaud's phenomenon
8
secukinumab-induced raynaud's
4
phenomenon report
4
report literature
4
literature secukinumab
4
secukinumab il-17a
4
il-17a antagonist
4
antagonist proven
4
proven efficacy
4
efficacy treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!